|Assembly Actions - Lowercase
Senate Actions - UPPERCASE
|Jan 08, 2020||referred to health|
|May 16, 2019||referred to health|
senate Bill S5923
Current Bill Status - In Senate Committee Health Committee
- In Committee
- On Floor Calendar
- Passed Senate
- Passed Assembly
- Delivered to Governor
- Signed/Vetoed by Governor
S5923 (ACTIVE) - Details
S5923 (ACTIVE) - Sponsor Memo
BILL NUMBER: S5923 SPONSOR: RIVERA TITLE OF BILL: An act to amend the social services law and the public health law, in relation to extending the preferred drug program to medi- caid managed care providers and offering the program to other health plans; and to repeal certain provisions of the social services law relating thereto PURPOSE OR GENERAL IDEA OF BILL: To provide the Medicaid drug benefit through utilization of the preferred drug program (PDP) under Public Health Law Art. 2-A, rather than through individual Medicaid managed care plan drug benefits. SUMMARY OF SPECIFIC PROVISIONS: The Preferred Drug Program under Public Health Law Art. 2-A would admin- ister the drug benefit for the whole Medicaid program, including negoti- ating rebates with drug companies seeking to have their drugs on the preferred drug list to avoid requiring private authorization. In order
S5923 (ACTIVE) - Bill Text download pdf
S T A T E O F N E W Y O R K ________________________________________________________________________ 5923 2019-2020 Regular Sessions I N S E N A T E May 16, 2019 ___________ Introduced by Sen. RIVERA -- read twice and ordered printed, and when printed to be committed to the Committee on Health AN ACT to amend the social services law and the public health law, in relation to extending the preferred drug program to medicaid managed care providers and offering the program to other health plans; and to repeal certain provisions of the social services law relating thereto THE PEOPLE OF THE STATE OF NEW YORK, REPRESENTED IN SENATE AND ASSEM- BLY, DO ENACT AS FOLLOWS: Section 1. Legislative findings. This legislature finds that the costs of many prescription drugs in the market have been escalating unreason- ably. The preferred drug program and the clinical drug review program under the public health law provide effective mechanisms for assuring access to quality, effective and safe drugs to patients at reasonable cost. Providing prescription drugs to Medicaid managed health care provider participants through these programs will maximize the Medicaid program's ability to negotiate more substantial rebates with drug manufacturers (effectively, lower prices), while protecting Medicaid managed care provider participants. Offering non-Medicaid health plans the opportunity to use these programs will help lower costs for those health plans and those who pay their premiums, while protecting individ- uals covered by those plans, and will also further increase the negoti- ating power of the programs. § 2. The social services law is amended by adding a new section 365-i to read as follows: § 365-I. PRESCRIPTION DRUGS IN MEDICAID MANAGED CARE PROGRAMS. 1. DEFINITIONS. (A) THE DEFINITIONS OF TERMS IN SECTION TWO HUNDRED SEVENTY OF THE PUBLIC HEALTH LAW SHALL APPLY TO THIS SECTION. (B) AS USED IN THIS SECTION, UNLESS THE CONTEXT CLEARLY REQUIRES OTHERWISE: (I) "MANAGED CARE PROVIDER" MEANS A MANAGED CARE PROVIDER UNDER SECTION THREE HUNDRED SIXTY-FOUR-J OF THIS ARTICLE, A MANAGED LONG TERM EXPLANATION--Matter in ITALICS (underscored) is new; matter in brackets [ ] is old law to be omitted.
Open Legislation comments facilitate discussion of New York State legislation. All comments are subject to moderation. Comments deemed off-topic, commercial, campaign-related, self-promotional; or that contain profanity or hate speech; or that link to sites outside of the nysenate.gov domain are not permitted, and will not be published. Comment moderation is generally performed Monday through Friday.
By contributing or voting you agree to the Terms of Participation and verify you are over 13.